Tradestie Institutional Equity Comparison Engine

LCTX vs RLAY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin while RLAY counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus RLAY at N/M Forward P/E and -3094.6% operating margin (-48.3% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against RLAY sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs RLAY N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -3094.6% ยท YoY -61.0% vs -48.3%
Momentum & Technical Winner RLAY
1Y -53.7% vs +144.4% ยท 52W Pos 4% vs 64%
Options & Structure Winner RLAY
BREAKDOWN (100th %ile IV) vs CONSOLIDATION (6th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
RLAY NASDAQ
Relay Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$15.91
-3.63% 1D
Market Cap $3.6B
1M Return -13.58%
1Y Return +144.39%
Forward P/E N/M
Unified AI Score
47.3 / 100 HOLD
Tech 35.0 Fund 58.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% RLAY +144.39% Spread: +198.06 pp (RLAY Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue RLAY Revenue LCTX Op. Margin RLAY Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $80M -1448.4% -67.5% RLAY
FY2021 $0M $0M -1133.6% -12040.2% LCTX
FY2022 $10M $0M -153.2% -21670.9% LCTX
FY2023 $10M $30M -276.5% -1460.1% LCTX
FY2024 $10M $10M -226.1% -3722.1% LCTX
FY2025 $10M $20M -251.6% -1971.6% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs RLAY (4)
Institutional Metric LCTX RLAY Criterion Row Winner
Market Capitalization Scale $212.1M $3.6B Larger Scale RLAY
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% -48.3% Higher Growth RLAY
Operating Margin (TTM) Profitability -280.3% -3094.6% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -41.2% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 64% ($6โ€“$21) Stronger Trend RLAY
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 1.74ฮฒ ยท 74% Vol Lower Realized Risk RLAY
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 47.3 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs RLAY Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RLAY CONSOLIDATION
104d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live RLAY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor RLAY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.